NASDAQ:SNGX Soligenix (SNGX) Stock Price, News & Analysis → What is the 72-Hour Profit Surge? (From DTI) (Ad) Free SNGX Stock Alerts $0.42 -0.01 (-1.76%) (As of 01:26 PM ET) Add Compare Share Share Today's Range$0.40▼$0.4250-Day Range$0.38▼$0.8252-Week Range$0.37▼$4.20Volume145,678 shsAverage Volume2.93 million shsMarket Capitalization$4.35 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Soligenix alerts: Email Address Soligenix MarketRank™ Stock AnalysisAnalyst Rating0.00 Rating ScoreUpside/Downside614.8% Upside$3.00 Price TargetShort InterestBearish8.00% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.50Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom $0.81 to ($0.68) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.25 out of 5 stars 2.0 Analyst's Opinion Amount of Analyst CoverageSoligenix has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.00% of the float of Soligenix has been sold short.Short Interest Ratio / Days to CoverSoligenix has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Soligenix has recently increased by 624.70%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSoligenix does not currently pay a dividend.Dividend GrowthSoligenix does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SNGX. Previous Next 1.9 News and Social Media Coverage News SentimentSoligenix has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Soligenix this week, compared to 1 article on an average week.Search Interest8 people have searched for SNGX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows1 people have added Soligenix to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Soligenix insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.36% of the stock of Soligenix is held by insiders.Percentage Held by InstitutionsOnly 3.60% of the stock of Soligenix is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Soligenix are expected to decrease in the coming year, from $0.81 to ($0.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Soligenix is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Soligenix is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSoligenix has a P/B Ratio of 1.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Soligenix Stock (NASDAQ:SNGX)Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.Read More SNGX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SNGX Stock News HeadlinesApril 25, 2024 | prnewswire.comSoligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South AfricaApril 18, 2024 | prnewswire.comSoligenix Announces Pricing of $4.75 Million Public OfferingApril 26, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.April 17, 2024 | investing.comSoligenix gains orphan drug status for MarVax vaccineApril 17, 2024 | finance.yahoo.comSage Therapeutics' Parkinson's drug fails in mid-stage studyApril 17, 2024 | finance.yahoo.comNanoscope Therapeutics to Present at the World Orphan Drug Congress 2024April 16, 2024 | benzinga.comSNGX: Agreement with EMA on Second Confirmatory Trial for HyBryte™April 16, 2024 | finanznachrichten.deSOLIGENIX, INC.: FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus InfectionApril 26, 2024 | DTI (Ad)What is the 72-Hour Profit Surge?One of the most overlooked opportunities in the stock market is the 72-Hour Profit Surge... A short period of time where we can bet on a stock that is ALREADY “winning.” Let me give you a perfect example of how the Surge worked with Ross Stores. Back on November 16th, a little move was made that sent their stock soaring… The next day, my system would have alerted me that Ross Stores had entered the 72-Hour Profit Surge…April 15, 2024 | finance.yahoo.comWhy Is Penny Stock Soligenix Trading Higher On Monday?April 15, 2024 | proactiveinvestors.comSoligenix surges as MarVax vaccine secures Orphan Drug Designation from FDAApril 15, 2024 | marketwatch.comSoligenix Shares Rise After SuVax Gets Orphan Drug Designation from US FDAApril 15, 2024 | markets.businessinsider.comSoligenix's MarVax Gets Orphan Drug DesignationApril 15, 2024 | msn.comSoligenix stock soars 106% on FDA orphan drug statusApril 15, 2024 | investorplace.comWhy Are Stocks Up Today?April 15, 2024 | investorplace.comWhy Is Soligenix (SNGX) Stock Up 58% Today?April 15, 2024 | finance.yahoo.comFDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus InfectionApril 11, 2024 | msn.comSolinex Down On Orphan Drug DesignationApril 11, 2024 | finance.yahoo.comSNGX: Agreement with EMA on Second Confirmatory Trial for HyBryte™…April 11, 2024 | markets.businessinsider.comSoligenix's SuVax Granted FDA Orphan Drug Designation For Prevention Of Sudan Ebolavirus InfectionApril 11, 2024 | prnewswire.comFDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus InfectionApril 3, 2024 | prnewswire.comSoligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines AgencyMarch 20, 2024 | finance.yahoo.comSNGX: Discussions Continue with FDA Regarding Second Phase 3 Study for HyBryte™ in CTCL…March 15, 2024 | investorplace.comSNGX Stock Earnings: Soligenix Beats EPS, Beats Revenue for Q4 2023March 15, 2024 | benzinga.comRecap: Soligenix Q4 EarningsMarch 15, 2024 | prnewswire.comSoligenix Announces Recent Accomplishments and Year End 2023 Financial ResultsFebruary 8, 2024 | finance.yahoo.comSoligenix Announces Formation of Behçet's Disease Medical Advisory BoardSee More Headlines Receive SNGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Soligenix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/15/2024Today4/26/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SNGX CUSIPN/A CIK812796 Webwww.soligenix.com Phone(609) 538-8200Fax609-452-6467Employees13Year Founded1987Price Target and Rating Average Stock Price Target$3.00 High Stock Price Target$3.00 Low Stock Price Target$3.00 Potential Upside/Downside+602.6%Consensus Rating Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)($0.90) Trailing P/E RatioN/A Forward P/E Ratio0.53 P/E GrowthN/ANet Income$-6,140,000.00 Net Margins-731.94% Pretax Margin-942.67% Return on Equity-251.07% Return on Assets-49.94% Debt Debt-to-Equity Ratio0.40 Current Ratio1.55 Quick Ratio1.52 Sales & Book Value Annual Sales$840,000.00 Price / Sales5.28 Cash FlowN/A Price / Cash FlowN/A Book Value$0.24 per share Price / Book1.78Miscellaneous Outstanding Shares10,380,000Free Float10,237,000Market Cap$4.43 million OptionableNot Optionable Beta1.81 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Christopher J. Schaber Ph.D. (Age 58)Chairman of the Board of Directors, CEO & President Comp: $625kMr. Jonathan L. Guarino CPA (Age 51)CGMA, Senior VP, CFO & Corporate Secretary Comp: $309.4kDr. Oreola Donini Ph.D. (Age 52)Senior VP & Chief Scientific Officer Comp: $342.31kDr. Richard C. Straube M.D. (Age 72)MSc., Senior VP & Chief Medical Officer Comp: $212.2kKey CompetitorsArtelo BiosciencesNASDAQ:ARTLEnsysce BiosciencesNASDAQ:ENSCZyVersa TherapeuticsNASDAQ:ZVSAHillstream BioPharmaNASDAQ:HILSLipella PharmaceuticalsNASDAQ:LIPOView All Competitors SNGX Stock Analysis - Frequently Asked Questions What is Soligenix's stock price target for 2024? 0 Wall Street analysts have issued 1 year price targets for Soligenix's stock. Their SNGX share price targets range from $3.00 to $3.00. On average, they expect the company's share price to reach $3.00 in the next year. This suggests a possible upside of 614.8% from the stock's current price. View analysts price targets for SNGX or view top-rated stocks among Wall Street analysts. How have SNGX shares performed in 2024? Soligenix's stock was trading at $0.7572 on January 1st, 2024. Since then, SNGX stock has decreased by 44.6% and is now trading at $0.4197. View the best growth stocks for 2024 here. Are investors shorting Soligenix? Soligenix saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 839,200 shares, an increase of 624.7% from the March 31st total of 115,800 shares. Based on an average daily volume of 2,560,000 shares, the days-to-cover ratio is currently 0.3 days. Approximately 8.0% of the company's stock are short sold. View Soligenix's Short Interest. When is Soligenix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our SNGX earnings forecast. How were Soligenix's earnings last quarter? Soligenix, Inc. (NASDAQ:SNGX) posted its earnings results on Friday, March, 15th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.03. The biopharmaceutical company earned $0.25 million during the quarter, compared to analyst estimates of $0.20 million. Soligenix had a negative net margin of 731.94% and a negative trailing twelve-month return on equity of 251.07%. What other stocks do shareholders of Soligenix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Soligenix investors own include VBI Vaccines (VBIV), T2 Biosystems (TTOO), Trevena (TRVN), Vaxart (VXRT), OPKO Health (OPK), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE) and Actinium Pharmaceuticals (ATNM). How do I buy shares of Soligenix? Shares of SNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SNGX) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soligenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
